Conference Day One

9.30 | Registration and Virtual Networking

9:55 am Chair’s Opening Remarks

10:00 am TIL Therapy: Current Status and Future Prospects

  • Laszlo Radvanyi President & Scientific Director, Ontario Institute for Cancer Research, University of Toronto


  • Overview of TIL therapy development and current state
  • Selecting the right TILs for therapy
  • Outstanding issues in TIL biology
  • Prevailing clinical challenges for TIL therapy

Biomarker & Target Identification to Improve T Cell Selection

10:30 am TIL Therapy Optimized for Tumor Reactive T-Cell Selection


  • Explore neoantigen identification approaches to achieve patient specific TIL therapy
  • Next generation approaches to improve TIL quality, especially in colder tumors

11:00 am Identification of Inhibigens™ May be the Key to Successful T Cell Therapies for Solid Tumors


  • Empirical antigen selection with ATLAS™ ensures that neoantigens are both presented by the tumor and immunogenic
  • Inhibigens, also identified with ATLAS, are targets of pro-tumor responses and can be avoided in cell therapies
  • GEN-011, a peripheral blood derived, neoantigen-targeted T cell therapy is currently being evaluated in patients with solid tumors in the TITAN-1 trial (NCT04596033)

11:30 am
Speed Networking & Refreshment Break


Like speed dating, but for business! Turn on your camera and randomly connect with speakers, delegates and partners of the conference so you can meet as many people as possible. Your random connection could lead to your next collaboration!

12:30 pm Origins, Features and Fates of Tumor-Reactive T Cells: Lessons from Ovarian Cancer

  • Brad Nelson Director & Distinguished Scientist, BC Cancer Deeley Research Centre


  • Properties of TIL when TMB is low and CNV is high
  • Evolution of TIL responses over time and treatment

1:00 pm Clinical Success of the TIL Technology Platform in Solid Tumors


  • Highlight advantages of polyclonal TIL MOA for solid tumors
  • Improving access to TIL using a proprietary, scalable, commerciallyviable manufacturing process
  • Review positive clinical data for TIL in metastatic melanoma and other solid tumor types
  • Explore next-generation approaches

1:30 pm Enriching for Tumor-Reactive CD8 TIL with CD39/103 Markers: Implications for TIL Therapy


  • CD39 and CD103 DP CD8 TIL highly enrich for tumor-specificity
  • Reactivity and recovery of function is associated with a 1-2 week incubation period
  • Discuss how these T cells represent a natural and diverse TCR repertoire to tumor antigens and can be found in most solid malignancies, although frequencies vary

2.00 pm | Refreshment Break & Networking

3:00 pm The Great Debate Roundtable Session: What Does the Optimal TIL Phenotype Look Like?

  • Jessica Chacon Assistant Professor, Texas Tech University Health Sciences Center


Collaborate with TIL experts to share experience and insights on the following critical questions:

  • How do we find the optimal TIL phenotype? – Anti-tumor activity and TIL differentiation status
  • How do we create the optimal TIL phenotype? – TIL engineering/reprogramming
  • Is it all about TIL phenotype? – Will the optimal TIL phenotype be clinically effective when attacking a “non T-cell permissive” tumor microenvironment?

Clinical Real World Experience

3:45 pm Clinical Challenges of TIL Therapy

  • Sylvia Lee Associate Professor, Program in Immunology, Clinical Research Division, Fred Hutch


  • Toxicity management of TIL therapy
  • Barriers to patient treatment
  • Patient selection and timing

4:15 pm Chair’s Closing Remarks

4.30 pm | Close of Day One